Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuyoshi Yamamoto

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Surgical Case Reports|September 28, 2016
Treatment of a giant inguinal hernia using transabdominal pre-peritoneal repairMasato Momiyama, Fumitoshi Mizutani, Tatsuyoshi Yamamoto, et al.
Zoological Science|August 31, 2004
Novel development rescuing factors (DRFs) secreted by the developing Dictyostelium cells, that are involved in the restoration of a mutant lacking MAP-kinase ERK2Masatsune Tsujioka, Tatsuyoshi Yamamoto, Christopher R Thompson, et al.
British Journal of Clinical Pharmacology|May 17, 2026
Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis IIKimitoshi Nakamura, Norio Sakai, Hideaki Hirai, et al.
Oncology Reports|June 18, 2002
Expression of p73 gene, cell proliferation and apoptosis in breast cancer: Immunohistochemical and clinicopathological studyTatsuyoshi Yamamoto, Koji Oda, Tomoyuki Kubota, et al.
Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology|July 8, 2026
Efficacy and safety of GH treatment in Japanese pediatric patients with <i>SHOX</i> deficiency: an open-label extension studyTsutomu Ogata, Sumito Dateki, Maki Fukami, et al.
Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology|April 4, 2024
Efficacy and safety of GH treatment in Japanese children with short stature due to <i>SHOX</i> deficiency: a randomized phase 3 studyTsutomu Ogata, Maki Fukami, Kazunori Tanizawa, et al.
Pharmaceutics|June 24, 2022
Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated TranscytosisHiroyuki Sonoda, Kenichi Takahashi, Kohtaro Minami, et al.
Molecular Genetics and Metabolism|May 12, 2020
Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studiesKimitoshi Nakamura, Satoshi Kawashima, Hirotaka Tozawa, et al.
JIMD Reports|November 12, 2021
Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case reportKazuyoshi Tomita, Shungo Okamoto, Toshiyuki Seto, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 1, 2019
Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 TrialTorayuki Okuyama, Yoshikatsu Eto, Norio Sakai, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Surgical Case Reports|September 28, 2016
Treatment of a giant inguinal hernia using transabdominal pre-peritoneal repairMasato Momiyama, Fumitoshi Mizutani, Tatsuyoshi Yamamoto, et al.
Zoological Science|August 31, 2004
Novel development rescuing factors (DRFs) secreted by the developing Dictyostelium cells, that are involved in the restoration of a mutant lacking MAP-kinase ERK2Masatsune Tsujioka, Tatsuyoshi Yamamoto, Christopher R Thompson, et al.
British Journal of Clinical Pharmacology|May 17, 2026
Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis IIKimitoshi Nakamura, Norio Sakai, Hideaki Hirai, et al.
Oncology Reports|June 18, 2002
Expression of p73 gene, cell proliferation and apoptosis in breast cancer: Immunohistochemical and clinicopathological studyTatsuyoshi Yamamoto, Koji Oda, Tomoyuki Kubota, et al.
Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology|July 8, 2026
Efficacy and safety of GH treatment in Japanese pediatric patients with <i>SHOX</i> deficiency: an open-label extension studyTsutomu Ogata, Sumito Dateki, Maki Fukami, et al.
Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology|April 4, 2024
Efficacy and safety of GH treatment in Japanese children with short stature due to <i>SHOX</i> deficiency: a randomized phase 3 studyTsutomu Ogata, Maki Fukami, Kazunori Tanizawa, et al.
Pharmaceutics|June 24, 2022
Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated TranscytosisHiroyuki Sonoda, Kenichi Takahashi, Kohtaro Minami, et al.
Molecular Genetics and Metabolism|May 12, 2020
Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase I and II/III clinical studiesKimitoshi Nakamura, Satoshi Kawashima, Hirotaka Tozawa, et al.
JIMD Reports|November 12, 2021
Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case reportKazuyoshi Tomita, Shungo Okamoto, Toshiyuki Seto, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 1, 2019
Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 TrialTorayuki Okuyama, Yoshikatsu Eto, Norio Sakai, et al.
Pageof 2